Share：
Share this content in WeChat
X
[Chinese] [PDF] 6 1
• Clinical Articles •
Value of diffusion weighted imaging-based habitat analysis for assessing isocitrate dehydrogenase mutation status in adult diffuse gliomas
WANG Huiting  TIAN Chuanshuai  ZHU Zhengyang  WU Junli  CHEN Futao  WANG Zhengge  ZHANG Xin  ZHANG Bing  CHEN Jiu 

Cite this article as: WANG H T, TIAN C S, ZHU Z Y, et al. Value of diffusion weighted imaging-based habitat analysis for assessing isocitrate dehydrogenase mutation status in adult diffuse gliomas[J]. Chin J Magn Reson Imaging, 2026, 17(3): 15-21. DOI:10.12015/issn.1674-8034.2026.03.003.


[Abstract] Objective To investigate the diagnostic value of diffusion weighted imaging (DWI)-based habitat imaging for the preoperative assessment of isocitrate dehydrogenase (IDH) mutation status in adult diffuse gliomas.Materials and Methods A total of 99 adult patients with diffuse gliomas (73 IDH wildtype and 26 IDH mutant) were retrospectively enrolled. Based on the intravoxel incoherent motion (IVIM) and diffusion kurtosis imaging (DKI) models, the perfusion fraction (f), true diffusion coefficient (D), and mean kurtosis (MK) parameters were calculated. K-means clustering was applied to voxel-wise data within the tumor volume of interest (VOI) to construct habitat maps, and the volumetric fraction of each habitat was quantified. Logistic regression was used to develop diffusion parameter model, habitat model, age model and integrated model. The performance of different models was evaluated using five-fold cross-validation. DeLong test was employed to compare the performance of the integrated model with that of the other models.Results The proportion of Habitat 1 (Hypercellular hypoperfusion hyperheterogeneous habitat) was higher in IDH wild-type gliomas compared with IDH mutant gliomas (0.56 ± 0.25 vs. 0.30 ± 0.20, P < 0.001), whereas the proportion of Habitat 2 (Hypocellular hypoperfusion hypoheterogeneous habitat) was lower (0.39 ± 0.25 vs. 0.64 ± 0.21, P < 0.001). DeLong test showed that the integrated model achieved the highest diagnostic performance [AUC = 0.902, 95% confidence interval (CI): 0.759 to 1.000]. Shapley additive explanations analysis indicated that age contributed most to model predictions, followed by the proportion of Habitat 1.Conclusions Habitat imaging based on IVIM and DKI parameters effectively reflects the intratumoral heterogeneity of gliomas. When combined with clinical characteristics, it enables accurate, noninvasive prediction of IDH mutation status, offering a promising imaging biomarker for preoperative molecular subtyping of gliomas.
[Keywords] glioma；isocitrate dehydrogenase；magnetic resonance imaging；diffusion-weighted imaging；habitat imaging

WANG Huiting1, 2   TIAN Chuanshuai1, 2   ZHU Zhengyang2   WU Junli3   CHEN Futao2   WANG Zhengge2   ZHANG Xin2   ZHANG Bing2   CHEN Jiu1, 2*  

1 Department of Radiology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 211166, China

2 Department of Radiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China

3 Department of Mathematics, Southeast University, Nanjing 210096, China

Corresponding author: CHEN J, E-mail: ericcst@aliyun.com

Conflicts of interest   None.

Received  2025-11-26
Accepted  2026-03-09
DOI: 10.12015/issn.1674-8034.2026.03.003
Cite this article as: WANG H T, TIAN C S, ZHU Z Y, et al. Value of diffusion weighted imaging-based habitat analysis for assessing isocitrate dehydrogenase mutation status in adult diffuse gliomas[J]. Chin J Magn Reson Imaging, 2026, 17(3): 15-21. DOI:10.12015/issn.1674-8034.2026.03.003.

[1]
HAN B F, ZHENG R S, ZENG H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.
[2]
HORBINSKI C, SOLOMON D A, LUKAS R V, et al. Molecular testing for the World Health Organization classification of central nervous system tumors: a review[J]. JAMA Oncol, 2025, 11(3): 317-328. DOI: 10.1001/jamaoncol.2024.5506.
[3]
LOUIS D N, PERRY A, WESSELING P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251. DOI: 10.1093/neuonc/noab106.
[4]
VAN DEN BENT M J, GEURTS M, FRENCH P J, et al. Primary brain tumours in adults[J]. Lancet, 2023, 402(10412): 1564-1579. DOI: 10.1016/S0140-6736(23)01054-1.
[5]
YAN H, PARSONS D W, JIN G L, et al. IDH1 and IDH2 mutations in gliomas[J]. N Engl J Med, 2009, 360(8): 765-773. DOI: 10.1056/NEJMoa0808710.
[6]
KACIMI S E O, DEHAIS C, FEUVRET L, et al. Survival outcomes associated with first-line procarbazine, CCNU, and vincristine or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma[J]. J Clin Oncol, 2025, 43(3): 329-338. DOI: 10.1200/JCO.24.00049.
[7]
KACHURI L, GUERRA G A, NAKASE T, et al. Genetic predisposition to altered blood cell homeostasis is associated with glioma risk and survival[J/OL]. Nat Commun, 2025, 16(1): 658 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/39809742/. DOI: 10.1038/s41467-025-55919-6.
[8]
JIANG T, NAM D H, RAM Z, et al. Clinical practice guidelines for the management of adult diffuse gliomas[J/OL]. Cancer Lett, 2021, 499: 60-72 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/33166616/. DOI: 10.1016/j.canlet.2020.10.050.
[9]
NELSON E J, GUBBIOTTI M A, CARLIN A M, et al. Clinical evaluation of IDH mutation status in formalin-fixed paraffin-embedded tissue in gliomas[J]. Mol Diagn Ther, 2023, 27(3): 371-381. DOI: 10.1007/s40291-022-00638-7.
[10]
KANG K M, SONG J, CHOI Y, et al. MRI scoring systems for predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion in adult-type diffuse glioma lacking contrast enhancement[J/OL]. Radiology, 2024, 311(2): e233120 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/38713025/. DOI: 10.1148/radiol.233120.
[11]
CAO M Q, WANG X Q, LIU F, et al. A three-component multi-b-value diffusion-weighted imaging might be a useful biomarker for detecting microstructural features in gliomas with differences in malignancy and IDH-1 mutation status[J]. Eur Radiol, 2023, 33(4): 2871-2880. DOI: 10.1007/s00330-022-09212-5.
[12]
SHENG Y R, DANG X F, ZHANG H, et al. Correlations between intravoxel incoherent motion-derived fast diffusion and perfusion fraction parameters and VEGF- and MIB-1-positive rates in brain gliomas: an intraoperative MR-navigated, biopsy-based histopathologic study[J]. Eur Radiol, 2023, 33(8): 5236-5246. DOI: 10.1007/s00330-023-09506-2.
[13]
ZHANG J, CHEN X W, CHEN D, et al. Grading and proliferation assessment of diffuse astrocytic tumors with monoexponential, biexponential, and stretched-exponential diffusion-weighted imaging and diffusion kurtosis imaging[J]. Eur J Radiol, 2018, 109: 188-195. DOI: 10.1016/j.ejrad.2018.11.003.
[14]
MAO C P, HU L X, JIANG W, et al. Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: a comparative study of four MRI diffusion models[J]. Eur Radiol, 2024, 34(4): 2546-2559. DOI: 10.1007/s00330-023-10198-x.
[15]
WANG X R, XIE Z H, WANG X Q, et al. Preoperative prediction of IDH genotypes and prognosis in adult-type diffuse gliomas: intratumor heterogeneity habitat analysis using dynamic contrast-enhanced MRI and diffusion-weighted imaging[J/OL]. Cancer Imaging, 2025, 25(1): 11 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/39923105/. DOI: 10.1186/s40644-025-00829-5.
[16]
LI S L, DAI Y M, CHEN J Y, et al. MRI-based habitat imaging in cancer treatment: current technology, applications, and challenges[J/OL]. Cancer Imaging, 2024, 24: 107 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/39148139/. DOI: 10.1186/s40644-024-00758-9.
[17]
HOFFMANN E, MASTHOFF M, KUNZ W G, et al. Multiparametric MRI for characterization of the tumour microenvironment[J]. Nat Rev Clin Oncol, 2024, 21(6): 428-448. DOI: 10.1038/s41571-024-00891-1.
[18]
LIU J, CONG C, ZHANG J, et al. Multimodel habitats constructed by perfusion and/or diffusion MRI predict isocitrate dehydrogenase mutation status and prognosis in high-grade gliomas[J/OL]. Clin Radiol, 2024, 79(1): e127-e136 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/37923627/. DOI: 10.1016/j.crad.2023.09.025.
[19]
VERMA R, HILL V B, STATSEVYCH V, et al. Stable and discriminatory radiomic features from the tumor and its habitat associated with progression-free survival in glioblastoma: a multi-institutional study[J]. AJNR Am J Neuroradiol, 2022, 43(8): 1115-1123. DOI: 10.3174/ajnr.A7591.
[20]
JEONG S Y, PARK J E, KIM N, et al. Hypovascular cellular tumor in primary central nervous system lymphoma is associated with treatment resistance: tumor habitat analysis using physiologic MRI[J]. AJNR Am J Neuroradiol, 2022, 43(1): 40-47. DOI: 10.3174/ajnr.A7351.
[21]
CHEN Y J, LIU N X, LIN R X, et al. Enhancing the prediction of axillary lymph node metastasis in breast cancer through habitat-based radiomics and voting algorithms[J]. Ultrasound Med Biol, 2026, 52(1): 133-141. DOI: 10.1016/j.ultrasmedbio.2025.09.001.
[22]
YANG Y C, WU J J, SHI F, et al. Sub-regional radiomics analysis for predicting metastasis risk in clear cell renal cell carcinoma: a multicenter retrospective study[J]. Acad Radiol, 2025, 32(1): 237-249. DOI: 10.1016/j.acra.2024.08.006.
[23]
WANG P, HUANG H, WU C Y, et al. The value of DKI and IVIM combined with clinical and conventional MRI features in predicting glioma IDH1 and 1p/19q molecular typing[J]. J Clin Radiol, 2025, 44(1): 33-40. DOI: 10.3969/j.issn.1001-9324.2025.1.lcfsxzz202501007.
[24]
JABEHDAR MARALANI P, MYREHAUG S, MEHRABIAN H, et al. Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma[J/OL]. Radiother Oncol, 2021, 156: 258-265 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/33418005/. DOI: 10.1016/j.radonc.2020.12.037.
[25]
LV X S, ZHAO H M, DONG Q R, et al. Application value of DKI in predicting IDH and TERT molecular subtypes of glioma[J]. Chin J CT MRI, 2023, 21(3): 6-8. DOI: 10.3969/j.issn.1672-5131.2023.03.003.
[26]
ZHANG L, JIN Z W, YANG F, et al. Added value of histogram analysis of intravoxel incoherent motion and diffusion kurtosis imaging for the evaluation of complete response to neoadjuvant therapy in locally advanced rectal cancer[J]. Eur Radiol, 2025, 35(3): 1669-1678. DOI: 10.1007/s00330-024-11081-z.
[27]
ZHU Z Y, WANG H, LI T X, et al. OMT and tensor SVD-based deep learning model for segmentation and predicting genetic markers of glioma: a multicenter study[J/OL]. Proc Natl Acad Sci U S A, 2025, 122(28): e2500004122 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/40627394/. DOI: 10.1073/pnas.2500004122.
[28]
NICHOLS L, TAVERNER T, CROWE F, et al. In simulated data and health records, latent class analysis was the optimum multimorbidity clustering algorithm[J/OL]. J Clin Epidemiol, 2022, 152: 164-175 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/36228971/. DOI: 10.1016/j.jclinepi.2022.10.011.
[29]
PANG H P, DANG X F, REN Y, et al. DKI can distinguish high-grade gliomas from IDH1-mutant low-grade gliomas and correlate with their different nuclear-to-cytoplasm ratio: a localized biopsy-based study[J]. Eur Radiol, 2024, 34(11): 7539-7551. DOI: 10.1007/s00330-023-10325-8.
[30]
WU Y Y, QU Z, YANG T, et al. Performance of simultaneous multislice diffusion-weighted imaging using monoexponential, intravoxel incoherent motion, and diffusion kurtosis models: assessment of microvascular invasion and histologic grade in hepatocellular carcinoma[J/OL]. Cancer Imaging, 2025, 25(1): 113 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/41013810/. DOI: 10.1186/s40644-025-00930-9.
[31]
GUO D, LIU L P, JIN Y. Prediction early recurrence of hepatocellular carcinoma after hepatectomy using gadoxetic acid-enhanced MRI and IVIM[J/OL]. Eur J Radiol Open, 2025, 14: 100643 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/40166482/. DOI: 10.1016/j.ejro.2025.100643.
[32]
CAI W, ZHU Y J, LI D F, et al. Intratumoral heterogeneity of CT enhancement for component prediction and prognostic significance in combined hepatocellular carcinoma-cholangiocarcinoma[J/OL]. Eur Radiol, 2025 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/41037071/. DOI: 10.1007/s00330-025-12034-w.
[33]
WANG C, NIU X W, XIA T Y, et al. Predicting c-KIT inhibitor efficacy in patient-derived models of sinonasal mucosal melanomas through integrated histogram analysis of whole-tumor DKI, IVIM, and DCE-MRI[J]. Clin Cancer Res, 2025, 31(9): 1686-1699. DOI: 10.1158/1078-0432.CCR-24-3765.
[34]
GONG X Q, WANG X X, WANG L, et al. Comparing multi-b-Value diffusion MRI models for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer[J/OL]. Radiology, 2025, 316(1): e242969 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/40693938/. DOI: 10.1148/radiol.242969.
[35]
ZHANG Y F, CHEN J J, YANG C, et al. Preoperative prediction of microvascular invasion in hepatocellular carcinoma using diffusion-weighted imaging-based habitat imaging[J]. Eur Radiol, 2024, 34(5): 3215-3225. DOI: 10.1007/s00330-023-10339-2.
[36]
ZHU F Y, ZHUO L Y, WANG T D, et al. Apparent diffusion coefficient predicts MGMT status in adult-type diffuse gliomas and is correlated with Ki-67 proliferation index[J/OL]. Front Oncol, 2025, 15: 1609562 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/40958862/. DOI: 10.3389/fonc.2025.1609562.
[37]
MEI X, CHEN Y S, ZHANG Q P, et al. Association between glioblastoma cell-derived vessels and poor prognosis of the patients[J]. Cancer Commun (Lond), 2020, 40(5): 211-221. DOI: 10.1002/cac2.12026.
[38]
HOOGSTRATE Y, DRAAISMA K, GHISAI S A, et al. Transcriptome analysis reveals tumor microenvironment changes in glioblastoma[J/OL]. Cancer Cell, 2023, 41(4): 678-692.e7 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/36898379/. DOI: 10.1016/j.ccell.2023.02.019.
[39]
READ R D, TAPP Z M, RAJAPPA P, et al. Glioblastoma microenvironment-from biology to therapy[J]. Genes Dev, 2024, 38(9/10): 360-379. DOI: 10.1101/gad.351427.123.
[40]
ZHAO H F, HOU Z G, HE Q F, et al. The diagnostic and prediction performance of MR diffusion kurtosis imaging in the glioma molecular classification: a systematic review and meta-analysis[J/OL]. Front Neurol, 2025, 16: 1543619 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/40352771/. DOI: 10.3389/fneur.2025.1543619.
[41]
ZHAO S S, WANG P P, GAO E Y, et al. Predicting IDH and 1p/19q molecular status of gliomas with multi-b values DWI[J/OL]. Front Oncol, 2025, 15: 1551023 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/40809035/. DOI: 10.3389/fonc.2025.1551023.
[42]
ZENG S M, MA H, XIE D X, et al. Tumor multiregional mean apparent propagator (MAP) features in evaluating gliomas-a comparative study with diffusion kurtosis imaging (DKI)[J]. J Magn Reson Imaging, 2024, 60(4): 1532-1546. DOI: 10.1002/jmri.29202.
[43]
YANG X F, LIN Y, SU Y, et al. Whole-tumor histogram analysis of diffusion weighted imaging, diffusion kurtosis imaging, and intravoxel incoherent motion for adult diffuse glioma genotyping[J/OL]. Cancer Imaging, 2025, 25(1): 111 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/40993831/. DOI: 10.1186/s40644-025-00931-8.
[44]
CHEN L, WU M, LI Y, et al. Assessment of MGMT and TERT subtypes and prognosis of glioblastoma by whole tumor apparent diffusion coefficient histogram analysis[J/OL]. Brain Behav, 2025, 15(1): e70175 [2025-11-25]. https://pubmed.ncbi.nlm.nih.gov/39739534/. DOI: 10.1002/brb3.70175.
[45]
DING Y J, ZHU H Q, LI Y H, et al. Continuous-time random walk and fractional order Calculus models histogram analysis of glioma biomarkers, including IDH1, ATRX, MGMT, and TERT, on differentiation[J]. Quant Imaging Med Surg, 2025, 15(7): 6118-6136. DOI: 10.21037/qims-2024-2725.

PREV MPRAGE combined with rs-fMRI in the study of brain damage in patients with type 2 diabetes mellitus and prediabetes
NEXT An experimental study of intravoxel incoherent motion diffusion-weighted imaging for evaluating the therapeutic effects of bone marrow mesenchymal stem cell in a rat model of peripheral nerve injury
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn